Springer Reference Medizin, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 13
Published: Dec. 20, 2024
Published: April 10, 2025
Abstract Depression (major depressive disorder) is widely recognised as a major public health problem around the world. The mainstay of treatment prescription antidepressants, although psychological treatments have place first‐line alternative to antidepressants in milder and moderate forms depression. This chapter concentrates on use offers advice drug choice, dosing, switching strategies sequencing treatments. near exclusion other non‐drug modalities does not imply any lack confidence their efficacy but simply reflects need (in prescribing guideline) concentrate medicines‐related subjects. Antidepressants are number anxiety spectrum disorders. Use selective serotonin reuptake inhibitors (SSRIs) preoperative period has been associated with 20% increase inpatient mortality, patient factors rather than could be excluded cause.
Language: Английский
Citations
7
Journal of Psychiatric Research, Journal Year: 2025, Volume and Issue: 183, P. 164 - 173
Published: Feb. 14, 2025
Language: Английский
Citations
1
Asian Journal of Psychiatry, Journal Year: 2024, Volume and Issue: 95, P. 103997 - 103997
Published: March 11, 2024
Language: Английский
Citations
8
BMC Pregnancy and Childbirth, Journal Year: 2025, Volume and Issue: 25(1)
Published: Feb. 6, 2025
Abstract Background Postpartum depression (PPD) is categorized by the Disorders-Fifth Edition as that begins during pregnancy or within first month after giving birth. Ketamine and esketamine have shown promising results in treatment of several depressive disorders, which suggests they may a role prevention PPD. This systematic review meta-analysis aim to update evidence about efficacy safety using ketamine reduce PPD incidence. Methods We searched four databases, PubMed, Scopus, Web Science, Cochrane, collect relevant studies. included studies investigated preventive effect on among women birth through caesarean vaginal delivery. extracted occurrence rate, score, pain score side effects. Finally, was conducted RevMan software. Results Twenty-one eligible were incorporated current involving 4,389 pregnant women. Esketamine intervention 14 studies, used 7 In subgroup analysis, both significantly effective reducing incidence short-term (ketamine: RR = 0.72, 95% CI [0.56, 0.93], P 0.01; esketamine: 0.43, < 0.0001). only reduced long-term (RR 0.44, 0.00001). Low doses high (high dose: 0.48, 0.0005; low 0.46, 0.002) 0.54, 0.0001; 0.61, 0.009). Regarding risk effects, patients Ketamine/esketamine group showed statistically significant higher rates developing dizziness ( 0.0007), blurred vision 0.02), vomiting 0.004) hallucinations 0,002) than control group. Conclusion Both are lowering On other hand, It recommended use smaller for more tolerable period since less 0.5 mg effective. Temporary effects such dizziness, vision, reported.
Language: Английский
Citations
0
JAMA Network Open, Journal Year: 2025, Volume and Issue: 8(2), P. e2459331 - e2459331
Published: Feb. 13, 2025
Importance Esketamine has been found to reduce the incidence of postpartum depression (PPD) in randomized clinical trials. However, current evidence from trials does not reflect esketamine’s efficacy settings. Objective To assess intraoperative esketamine administration for preventing PPD among women who underwent cesarean delivery. Design, Setting, and Participants This trial was conducted at The First Affiliated Hospital Chongqing Medical University Chongqing, China, March 2023 February 2024. Pregnant patients admitted delivery were included, while those with intellectual dysfunction or contraindications excluded. All participants assigned randomly either group control a 1:1 ratio. Data analysis based on intention-to-treat principle. Interventions Patients received an infusion 0.25 mg/kg 20 mL saline over minutes, whereas minutes. Main Outcomes Measures primary outcome 6 weeks post partum. assessed using Edinburgh Postnatal Depression Scale. Results A total 308 pregnant 1 2 groups: (n = 154; mean [SD] patient age, 31.57 [4.26] years) 32.53 [7.74] years). Incidence significantly lower compared partum (10.4% [16] vs 19.5% [30]; relative risk, 0.53; 95% CI, 0.30-0.93; P .02). Conclusions Relevance demonstrated advantage reducing safety warrant further investigation practice. Trial Registration Chinese Clinical Registry Identifier: ChiCTR2200065494
Language: Английский
Citations
0
CNS Spectrums, Journal Year: 2024, Volume and Issue: 29(5), P. 326 - 334
Published: Oct. 1, 2024
Abstract Objective Postpartum depression (PPD), now referred to as perinatal depression, is a prevalent and debilitating mood disorder that reduces health-related quality of life (HRQoL) psychosocial functioning. Esketamine, which efficacious in adults with treatment-resistant individuals suicidality, also analgesic pain management during childbirth labour. Herein, we investigate the efficacy prophylactic esketamine reducing incidence PPD. Methods We performed systematic review (i.e., PubMed, Scopus, Ovid databases; inception January 22, 2024) randomized controlled trials investigated use for delimited our search studies prespecified prevention PPD primary outcome. A meta-analysis was on rates using random effects model. Results Our analysis consisted seven met eligibility criteria. found significantly associated decreased diagnosis within one week (OR = 0.30, 95% CI [0.15, 0.60], p 0.0047). observed between 4 6 weeks post-delivery 0.33, [0.18, 0.59], 0.0034). Conclusion results indicate may have preventive antidepressant postpartum period. The aforementioned points both mechanistic clinically meaningful implications treatment
Language: Английский
Citations
2
Psychiatry Research Communications, Journal Year: 2024, Volume and Issue: 4(3), P. 100190 - 100190
Published: Aug. 29, 2024
Language: Английский
Citations
0
Published: Jan. 1, 2024
Language: Английский
Citations
0
Springer Reference Medizin, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 13
Published: Dec. 20, 2024
Citations
0